Pregled bibliografske jedinice broj: 1074117
ADVERSE DRUG REACTIONS OF PSYCOPHARMACS
ADVERSE DRUG REACTIONS OF PSYCOPHARMACS // Psychiatria Danubina, 22 (2010), 3; 441-445 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1074117 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
ADVERSE DRUG REACTIONS OF PSYCOPHARMACS
Autori
Mirošević Skvrce, Nikica ; Arapović, Selma ; Krnić, Darko ; Macolić Šarinić, Viola ; Žeželić, Saša ; Bagatin, Krešimir ; Leventić, Jelena ; Tomić, Siniša
Izvornik
Psychiatria Danubina (0353-5053) 22
(2010), 3;
441-445
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
adverse drug reaction ; psycopharmacs ; seriousness ; safe use of medicinal products
Sažetak
Background: The objective of analysis of ADRs caused by drugs that pertain to the ATC group N (nervous system), as reported to the Croatian Agency for Medicinal Products and Medical Devices for the period from March 2005 to December 2008, was to examine the types of ADRs collected in said period, the profile of reporters and the possible impacts this could have on prescribing this group of medicinal products in the future. Subjects and methods: A retrospective observational study of ADRs was performed. Drugs causing ADRs were grouped according to the ATC drug classification, and subsequently entered into a database. Data were analyzed in respect of total number, gender, age, type, seriousness, expectedness, outcome, system organ class, suspected drug and reporter. Results: The findings showed that 15% of all reported ADRs were caused by drugs from the ATC group N. 60% of these were caused by drugs belonging to the ATC subgroups N05 (psycholeptics) and N06A (antidepressants). A significant increase in the percentage of serious ADRs in the examined groups of medicinal products was observed. Analysis of expectedness showed that the share of unexpected ADRs is very high. Conclusion: The distribution of reporters is not satisfactory. The Agency, as regulatory authority, cannot undertake certain measures to improve the safe use of medicinal products without having reports. Only reporting of ADRs can result in changes to benefit all patient populations. Our joint aim should be avoiding a great number of ADRs and maintaining overall safe use of medicinal products.
Izvorni jezik
Engleski
Znanstvena područja
Farmacija
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- Social Science Citation Index (SSCI)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE